Literature DB >> 22224767

Pathogenesis of human B cell lymphomas.

Arthur L Shaffer1, Ryan M Young, Louis M Staudt.   

Abstract

The mechanisms that drive normal B cell differentiation and activation are frequently subverted by B cell lymphomas for their unlimited growth and survival. B cells are particularly prone to malignant transformation because the machinery used for antibody diversification can cause chromosomal translocations and oncogenic mutations. The advent of functional and structural genomics has greatly accelerated our understanding of oncogenic mechanisms in lymphomagenesis. The signaling pathways that normal B cells utilize to sense antigens are frequently derailed in B cell malignancies, leading to constitutive activation of prosurvival pathways. These malignancies co-opt transcriptional regulatory systems that characterize their normal B cell counterparts and frequently alter epigenetic regulators of chromatin structure and gene expression. These mechanistic insights are ushering in an era of targeted therapies for these cancers based on the principles of pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22224767      PMCID: PMC7478144          DOI: 10.1146/annurev-immunol-020711-075027

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  367 in total

Review 1.  CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.

Authors:  Margot Thome
Journal:  Nat Rev Immunol       Date:  2004-05       Impact factor: 53.106

Review 2.  B cell antigen receptor signaling 101.

Authors:  Joseph M Dal Porto; Stephen B Gauld; Kevin T Merrell; David Mills; Aimee E Pugh-Bernard; John Cambier
Journal:  Mol Immunol       Date:  2004-07       Impact factor: 4.407

Review 3.  Chromatin modifications and their function.

Authors:  Tony Kouzarides
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

4.  p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.

Authors:  U Klangby; I Okan; K P Magnusson; M Wendland; P Lind; K G Wiman
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

5.  The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence.

Authors:  Lixin Hong; Maoyi Lai; Michelle Chen; Changchuan Xie; Rong Liao; Young Jun Kang; Changchun Xiao; Wen-Yuan Hu; Jiahuai Han; Peiqing Sun
Journal:  Cancer Res       Date:  2010-09-17       Impact factor: 12.701

6.  Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.

Authors:  Giorgio Cattoretti; Laura Pasqualucci; Gianna Ballon; Wayne Tam; Subhadra V Nandula; Qiong Shen; Tongwei Mo; Vundavalli V Murty; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

Review 7.  Biology and treatment of Burkitt's lymphoma.

Authors:  Jason T Yustein; Chi V Dang
Journal:  Curr Opin Hematol       Date:  2007-07       Impact factor: 3.284

Review 8.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

9.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.

Authors:  G Liu; A Bollig-Fischer; B Kreike; M J van de Vijver; J Abrams; S P Ethier; Z-Q Yang
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

10.  Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors.

Authors:  Katia Basso; Arcangelo Liso; Enrico Tiacci; Roberta Benedetti; Alessandro Pulsoni; Robin Foa; Francesco Di Raimondo; Achille Ambrosetti; Andrea Califano; Ulf Klein; Riccardo Dalla Favera; Brunangelo Falini
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

View more
  173 in total

1.  Upregulation of nuclear transporter, Kpnβ1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma.

Authors:  Song He; Xiaobing Miao; Yaxun Wu; Xinghua Zhu; Xianjing Miao; Haibing Yin; Yunhua He; Chunsun Li; Yushan Liu; Xiaoyun Lu; Yali Chen; Yuchan Wang; Xiaohong Xu
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-23       Impact factor: 4.553

2.  Bone marrow stromal cells induced activation of nuclear factor κB signaling protects non-Hodgkin's B lymphoma cells from apoptosis.

Authors:  Tuo Su; Jiakai Li; Mingming Meng; Sheng Zhao; Yali Xu; Xinmin Ding; Hong Jiang; Xiaorong Ma; Jin Qian; Wei Han; Lixin Sun; Xiaobin Li; Zuojun Liu; Lei Pan; Xinying Xue
Journal:  Tumour Biol       Date:  2016-02-12

3.  ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.

Authors:  Karen S Hathcock; Hesed M Padilla-Nash; Jordi Camps; Dong-Mi Shin; Daniel Triner; Arthur L Shaffer; Robert W Maul; Seth M Steinberg; Patricia J Gearhart; Louis M Staudt; Herbert C Morse; Thomas Ried; Richard J Hodes
Journal:  Blood       Date:  2015-09-23       Impact factor: 22.113

4.  CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.

Authors:  Andreas Herrmann; Christoph Lahtz; Toshikage Nagao; Joo Y Song; Wing C Chan; Heehyoung Lee; Chanyu Yue; Thomas Look; Ronja Mülfarth; Wenzhao Li; Kurt Jenkins; John Williams; Lihua E Budde; Stephen Forman; Larry Kwak; Thomas Blankenstein; Hua Yu
Journal:  Cancer Res       Date:  2017-07-17       Impact factor: 12.701

5.  AID-associated DNA repair pathways regulate malignant transformation in a murine model of BCL6-driven diffuse large B-cell lymphoma.

Authors:  Xiwen Gu; Carmen J Booth; Zongzhi Liu; Matthew P Strout
Journal:  Blood       Date:  2015-09-18       Impact factor: 22.113

6.  IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis.

Authors:  Elisa Ferretti; Emma Di Carlo; Emanuela Ognio; Giulio Fraternali-Orcioni; Anna Corcione; Beatrice Belmonte; Jean Louis Ravetti; Claudio Tripodo; Domenico Ribatti; Vito Pistoia
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

7.  Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.

Authors:  Sharvil P Patel; R Andrew Harkins; Michelle J Lee; Christopher R Flowers; Jean L Koff
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-12-24

8.  Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

Authors:  Shyril O'Steen; Damian J Green; Ajay K Gopal; Johnnie J Orozco; Aimee L Kenoyer; Yukang Lin; D Scott Wilbur; Donald K Hamlin; Darrell R Fisher; Mark D Hylarides; Theodore A Gooley; Amelia Waltman; Brian G Till; Oliver W Press
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

9.  Downregulation of FOXP1 is required during germinal center B-cell function.

Authors:  Ainara Sagardoy; Jose I Martinez-Ferrandis; Sergio Roa; Karen L Bunting; María Angela Aznar; Olivier Elemento; Rita Shaknovich; Lorena Fontán; Vicente Fresquet; Ignacio Perez-Roger; Eloy F Robles; Linde De Smedt; Xavier Sagaert; Ari Melnick; Jose A Martinez-Climent
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

Review 10.  Protein kinase inhibitors against malignant lymphoma.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.